https://www.clinicaltrialsarena.com/news/renalys-pharma-filspari-iga-nephropathy-phase-iii/
Nov 27, 2025 - Renalys Pharma will now submit a NDA to Japanese regulators for Filspari, which is set to bring in $1.44bn in sales during 2031, GD estimates
phase iiiiga nephropathyeyesjapanesefilspari